Evidence map›Paper›PMID 42818584›Full record

ArticlebioRxiv : the preprint server for biology2026

An RBP-J-heparan sulfate-dependent gatekeeper directs macrophage fate between inflammatory regulation and osteoclastogenesis.

Ting Zheng, Huanmeng Hao, Jialin Jiang, Zhangjie Wang, Miaomiao Li, Courtney Ng, Jian Liu, Ding Xu, Baohong Zhao

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ting ZhengArthritis and Tissue Degeneration Program and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, USA.ORCID 0000-0001-7723-7653
Huanmeng HaoDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, GA, USA.
Jialin JiangArthritis and Tissue Degeneration Program and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, USA.
Zhangjie WangGlycan Therapeutics Corporation, Raleigh, NC, USA.
Miaomiao LiDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, the State University of New York, Buffalo, NY, USA.
Courtney NgArthritis and Tissue Degeneration Program and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, USA.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Ding XuDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, GA, USA.
Baohong ZhaoArthritis and Tissue Degeneration Program and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, USA.

Funding

Regulation of Osteoclastogenesis and Arthritic Bone Resorption by RBP-JR01AR071463 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI Baohong Zhao · 2017 to 2026
$4.0M
The role of heparan sulfate in cathepsin K biologyR01DE031273 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JIAN LIU, Ding Xu · 2022 to 2026
$2.7M
Regulation of bone homeostasis and remodeling by long noncoding RNA Malat1R01AR078212 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI Baohong Zhao · 2021 to 2026
$2.2M
Development of analytical methods for glycosaminoglycans from biological sourcesR44GM142304 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI WANG, ZHANGJIE · 2022 to 2023
$2.0M
Quantitative analysis of heparan sulfate using 13C-labeled standardsR43GM142304 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2021 to 2021
$300k
NIAMS NIH HHS R01 AR071463NIAMS NIH HHS R01 AR078212NIDCR NIH HHS R01 DE031273NIGMS NIH HHS R43 GM142304NIGMS NIH HHS R44 GM142304
6 · The paper itself

Abstract

Macrophages in bone possess a unique bi-potential capacity. Different from their primary roles in inflammation and immunity, these cells can differentiate into bone-resorbing osteoclasts. However, it remains unclear how macrophages determine which function to engage in bone, especially when exposed to the same stimulus, such as TNF, which can drive both pathways. Understanding these mechanisms is particularly important in inflammatory bone diseases, such as rheumatoid arthritis, where inflammation and bone resorption are hallmarks. Here, we identified an RBP-J-Hs2st1-2-O-sulfated heparan sulfate (HS)-IFNβ dependent molecular network that acts as a gatekeeper balancing macrophage fate inclinations in response to TNF. This network integrates cellular outside-in, inside-out, and relayed outside-in pathways. RBP-J deficiency in macrophages shifts TNF action from inflammatory regulation to osteoclastogenesis. Hs2st1, the exclusive biosynthetic enzyme for 2-O sulfation of HS, is a key target suppressed by RBP-J. Loss of Hs2st1 significantly reduces inflammatory osteoclastogenesis and arthritic bone erosion without affecting physiological bone mass. Elevated Hs2st1 expression and 2-O sulfation shift macrophages toward an osteoclastogenic fate, and vice versa. We further identified residues in IFNβ that are responsible for binding HS. Mutation of these sites diminished HS binding, augmented type I IFN response, and more strongly suppressed osteoclastogenesis. Our findings reveal a previously unrecognized molecular program fine-tuning macrophage fate and function, and highlight potential therapeutic strategies for inflammatory diseases with bone defects.

Identifiers

PMID42818584
PMCPMC13622539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.